
Conference Coverage
Latest Content

Shorts










Podcasts
Videos
All News

Nuvalent submitted an NDA for neladalkib to the FDA for patients with previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 trial data showing activity.

Histotripsy uses focused ultrasound to treat liver tumors without surgery, needles or radiation, offering a new non-invasive option for patients.

Dr. Sara Nunnery and Dr. Neil Iyengar discuss metabolic health, GLP-1s and prescribing exercise to improve outcomes for breast cancer survivors.

Dry mouth and neck tightness from oral tongue cancer treatment shape daily life, managed with hydration, stretches, therapies and a head and neck Flexitouch device.

My experience with small lymphocytic lymphoma for the past 16 years has taught me many lessons.

Expanding local access to clinical trials improves options by reducing barriers and bringing research opportunities closer to patients with cancer, Dr. Natalie Berger said.

Following her breast cancer diagnosis, Guerdy Abraira utilized genomic testing to gain clarity on her treatment path.

Diabetes drug metformin may mimic exercise effects in prostate cancer, supporting weight, metabolism and overall health during treatment.

Research shows lifestyle and gut bacteria may drive early-onset colorectal cancer, emphasizing diet and healthy habits to help lower risk.

Learn about inflammatory breast cancer (IBC) diagnosis, aggressive treatment paths, and side effects to better navigate your journey and care plan.

Dr. Robert Coleman explains how Lifyorli plus nab-paclitaxel may help patients with platinum-resistant ovarian cancer control disease and improve survival.

If a car had a 50% chance of crashing, I would never let my son in it. With a hereditary cancer syndrome, though, there's no safety feature to lessen the odds. The mutation is simply there, or it isn't.

Dr. Gregory Tiesi discusses TAMP, a targeted therapy that delivers chemotherapy directly to pancreatic tumors with fewer side effects.

A kidney cancer survivor shares how a decade of breakthroughs in immunotherapy and targeted research transformed a death sentence into a life saved.

CTIM-76 has received FDA fast track designation for platinum-resistant ovarian cancer, a step aimed at accelerating development for patients with few options.




















